Sleuth
Intel Hub · Protein Degraders · Q3 2026

The full analysis behind our Q3 2026 Protein Degraders Intel Hub, with the data under every slide, as of September 2026. Click any bar, dot, card or event to see what sits behind it.

The Excel behind this report is free for Sleuth Intelligence Community members. Get the Excel

How many degraders are in the clinic, and where have they won approval?

Institution region
Approved degraders by year of first cancer approval
Class

Which degrader mechanisms have reached each stage in cancer?

Mechanism
ER degraders' Phase 3 hazard ratios
Progression-free survival in ESR1-mutant breast cancer; lower favors the degrader. Click a drug for its trial.

Which oncology PROTACs are in the clinic, who owns them, and how far have they got?

Stage
Sponsor
Target

Where do late-stage cancer degraders cluster?

Phase
Show

Where have degraders won, and how close are the other validated targets?

Group

Did degrader deals buy platforms or drugs, and where did the upfront cash go?

Show
Yearsto
Modality

When do degraders help patients whose tumors resist current drugs?

Outlook
Degraders stopped where a drug is already approved

Through 2027, which new target could get a first degrader approval?

Event type

Have degrader-antibody conjugates (DACs) worked in patients yet?

Payload degrades

In myeloma, what answers IMiD resistance: stronger CRBN glues or new E3 ligases?

Share of patients whose CRBN is altered. Click a stage for the basis.
Click a drug for its Phase 3 design.
Ligase

What do we expect next?

Explore the Data Behind the Report

The Excel behind this report (Clinical Degrader Programs, Oncology PROTAC Map, Deals, and DAC Programs) is free for Sleuth Intelligence Community members. Not a member yet? Join the community.